Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Hemangiosarcoma × Urination × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Prostatic Neoplasms 3 Disease 2 Colorectal Neoplasms 2 Acute Kidney Injury 2 Tuberous Sclerosis 1 Smoldering Multiple Myeloma 1 Salivary Gland Adenoma, Pleomorphic 1 Renal Insufficiency 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Neoplasms, Plasma Cell 1 Neoplasms 1 Monoclonal Gammopathy of Undetermined Significance 1 Lymphangioleiomyomatosis 1 Lung Neoplasms 1 Kidney Neoplasms 1 Hemangiosarcoma 1 Gallbladder Neoplasms 1 Cholangiocarcinoma 1 Carcinoma, Pancreatic Ductal 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

Paclitaxel 6 Doxorubicin 5 pembrolizumab 4 pazopanib 4 Gemcitabine 4 durvalumab 3 Propranolol 3 Docetaxel 3 Surveys and Questionnaires 2 Sunitinib 2 Standard of Care 2 Radiotherapy 2 Nivolumab 2 Ifosfamide 2 Bevacizumab 2 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 2 zanidatamab 1 veliparib 1 tucatinib 1 trilaciclib 1 tremelimumab 1 trebananib 1 trastuzumab duocarmazine 1 talazoparib 1 spartalizumab 1 sintilimab 1 selinexor 1 sarilumab 1 ribociclib 1 regorafenib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01786889 2016-07-29

ANGIHE

Centre Oscar Lambret

Phase NA Unknown

Hemangiosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡